Member Info for PCS1954

Agree Num4, I do hope TM is not solo at Bio Europe - irrespective of what is being presented JR’s deliverance far superior imho.

GLA

With the presentation events and the peer review alluded to by Laz and HBD it would be great if there was a connection in timelines, peer review due in this quarter, which given Festive break, could possibly mean this month!

JR did state it’s being worked on now and in the slide presentation.

GLA

Concur with your post Benhowell !

GLA

Morning stevej

“Nothing but positive news within the next 3 months, which will change the company and share price

Just my opinion but after 16 years in here, I’ve got to be right once 🤣”

Likewise, after 15 years I think we may be on the brink of fulfilling the business plan, lots of positives to consider!

Get the “emotional moochers” will negate where they can, but, given yesterday’s main talking point for them was toxicology Q2 or Q3 when we haven’t even got a start date (other than JR saying as soon as possible) confirms the hot air they seek to blow!

Looking forward to the next 3 months and meeting up with some of you at the AGM!

GLA

Very reassured with yesterday, SP and JR gave a clear and precise update of where we are and the intended pathway!

GLA

Couldn’t agree more HBD, think SP may just have won a few friends !!

GLA

Yes he did!!

GLA

Exactly Jules, for once a clear message and timelines!

GLA

Hi Hopkirk

Trust you are well, yes missed that on first read!!

GLA

Hi Bobbler

In fairness, it is mentioned in the full statement as below.

Overall, I think the RNS is very low key, deliberately?? as not usual SP - who knows!!

“The Board of Sareum continues to apply a rigorous approach to capital allocation in the development of the Company's assets. The Company maintains a clear focus on advancing these potential medicines to patients as efficiently as possible while maximizing value for shareholders.”

GLA

Agree Bobbler, I note no mention of “talking to interested parties” which must be a first!

Makes for an intriguing IMC question and answer time for SP this afternoon.

GLA

Hi Celtic

I’m hoping that is answered in the Y/E update rather than a question needed to be raised.

There has been some poignant comments on the bb today from both sides of the “fence”, I’m hoping that with SP in the chair we get a clear update and indicative pathway of where we are and where we are aiming to go - I certainly do not expect “we didn’t think we needed to say anything “ as per TM’s response to my questioning of SRA737 data return and update at the last AGM.

I do believe knowing the AGM is probably only 7 weeks away and with new “investors” onboard who I’m sure would not have put money in blindly SP will provide a proper appraisal, if not, the AGM could be interesting!!

Hopefully, good clear direction tomorrow, people can make judgment and Sareum moves on positively both in the “Lab” and the “Market”.

GLA

Apologies, a very late good evening Horse 1

A very valid post and thanks for sharing - likewise, I have asked where the mentioned “studies” are to take place - hopefully, Tuesday will be very interesting all for the right reasons!

GLA

Yep, I now acknowledge your point - I’m looking at it that the extra toxic studies are part of the process for 2a regulatory requirement.

Either way the studies come at a cost, which we obviously didn’t have funds for, but now do!

Hopefully, a clearer statement on Tuesday!!

GLA

Hi Potnak which RNS please as I don’t recall SP saying such - thanks in advance.

Enjoy Pembrokeshire!

GLA

I might be missing something but, my recollection was that JR stated we may “miss out” P1b if data good and go straight to P2 - the RNS stated to “prepare the asset for P2 trials” so I’m taking that as a positive - rightly or wrongly, but, that’s what the RNS says!

Also, if problems/lacking detail with toxicology studies in P1a, then the BoD have done a bloody good job in convincing the “Investors” on board.

I’m still of the opinion it is a third party requirement to “get ready for P2” -who knows and it’s only my opinion, I also appreciate others will have different views.

Have a good weekend.

GLA

Totally agree Shepherddollar, no use dwelling over things you can’t change - for me questioning comes after update and what it contains - hopefully, good!

Best of luck with your additional holding.

GLA

Evening HBD

Good read and reasoned analogy there, since Krone highlighted Treeline I’ve been having a read up about them - seem a very innovative set up, both scientifically and financially.

Obviously, just my opinion but could be interesting if that’s the route CRT have taken with SRA737.

GLA

Hi blueandwhite certainly agree with your comment regarding “knowledgeable analysts” and hence my current support to SP for obtaining the current funding.

Also, going this route would be on the back of approval via the NED and going to ready investors via the broker, accept pi’s have missed out but not sure there would be too many readily able to invest such numbers, also time element.

I’m not chasing a £bn valuation, so my strategy is still in play providing Sareum are to move forward, which, hopefully they are!

GLA

The extended toxicology studies are a regulatory requirement if SDC - 1801 is to progress in further trials - what’s not to say there is a deal in the background subject to reaching that hurdle.

Given the raise has been achieved quickly and further monies to reboot SDC-1802, I’m okay with that - I’m also happy to wait for SP to present his statement on Tuesday!

GLA